TrialSignal transduction and targeted therapy2023

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.

Yunpeng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.